Clinical results with two different pharmaceutical preparations of riboflavin in corneal cross-linking: an 18-month follow up by unknown
Hashemi et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:4 
DOI 10.1186/s40199-015-0091-zRESEARCH ARTICLE Open AccessClinical results with two different pharmaceutical
preparations of riboflavin in corneal cross-linking:
an 18-month follow up
Hassan Hashemi1*, Mohammad Amin Seyedian1, Mohammad Miraftab1, Hooman Bahrmandy1, Araz Sabzevari1
and Soheila Asgari2Abstract
Background: Comparison of long-term clinical results of two different pharmaceutical formulations used in corneal
cross-linking (CXL) in keratoconus patients.
Methods: Sixty eyes of 60 keratoconus patients underwent CXL in two groups. We used riboflavin preparations
from Sina Darou, Iran in group A, and Streuli Pharma, Switzerland in group B. Here we made inter-group comparison
of changes in vision, refraction, Pentacam indices, corneal biomechanical indices, and endothelial cell count (ECC)
18 months after CXL.
Results: Since four patients were lost to follow-up, 56 eyes (28 eyes in each group) were compared. Mean improvement
in uncorrected visual acuity (UCVA) was 0.31 ± 0.65 LogMAR (P = 0.014) in group A and 0.24 ± 0.62 LogMAR (P = 0.082) in
group B. Best corrected visual acuity (BCVA) remained quite unchanged in both groups (P = 0.774). Mean spherical
refractive error reduced by 0.45 ± 1.15 diopter (D) (P = 0.041) in group A and 0.27 ± 1.73 D (P = 0.458) in group B
(P = 0.655). Cylinder error and spherical equivalent had a similar trend without any change. Max-K (P = 0.006) and
mean-K (P = 0.044) decreased significantly more in group A compared to group B. The reduction in CCT was
significantly more in group A than group B (P = 0.004). Q-value was quite unchanged in both groups (P = 0.704).
The inter-group difference in CH reduction was borderline significant statistically (P = 0.057). Changes in corneal
resistance factor and endothelial cell count were not significantly different between two groups (P = 0.117 and
P = 0.229).
Conclusion: Clinical results of CXL with the domestic preparation of riboflavin are similar to that achieved with the
Swiss made product in some aspects, and it is the preferred brand in some other aspects. This study will continue
to report longer follow-up results.
Trial registration: IRCT201212034333N2
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Collagen cross linking with riboflavin (CXL) was first
developed by Wollensak et al. [1] to stop the progression
of keratoconus. In this procedure, riboflavin plays an
important role because it absorbs UVA and it reduces
cell damage [1]. The riboflavin preparation used in Iran
is a product of Streuli Pharma, a Swiss company. Export* Correspondence: hhashemi@norc.ac.ir
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unless otherwise stated.company of Sina Darou has manufactured this product
in Iran with the same formulation and amount of active
substance as the Swiss equivalent, and we have studied
its clinical results in patients treated with CXL. In the
preliminary report [2], we demonstrated that 6-month
changes in vision, refraction, K-reading, corneal biomech-
anics, and endothelial cell count parameters were not
significantly different between the two groups, and clinical
results achieved with these formulations are similar.
Here we compare 18-month results between these twoal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Hashemi et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:4 Page 2 of 5preparations, so that we can comment on their clinical
use with better certainty.
Methods
The complete study methodology has previously been
described [2]. In brief, we enrolled 60 eyes of 60 kerato-
conus patients (30 eyes in each group) in this parallel
non-randomized clinical trial. The Iranian preparation of
riboflavin 0.1% (Sina Darou, Iran) was used in the first
group (group A), and the Swiss preparation of riboflavin
0.1% (Streuli Pharma, Uznach, Switzerland) was used in
the second group (group B) during the procedure. Inclu-
sion criteria were the diagnosis of progressive keratoco-
nus on clinical exam which is confirmed paraclinically,
age between 15 and 35 years, keratometry less than 55.0
diopter (D), and a minimum central corneal thickness
(CCT) of 400 microns (μm).
First the study methods and objectives were explained
to the subjects, and they were enrolled in the study after
obtaining written informed consents. The study was
approved by Noor Review Board. Iranian Registry of Clin-
ical Trials also approved the study (registration number:
IRCT201212034333N2).
The surgical procedure has already been described [3].
After local anesthesia, 3 or 4 strips 2 millimeter wide, and
about 1 millimeter apart were removed from the central 7
millimeter of the cornea, leaving the corneal epithelial in-
tact in-between. Another epithelium strip was removed
horizontally from the inferior third of the cornea. Then,
riboflavin 0.1% drops in 20% dextran were instilled onto
the corneal surface for half an hour at 3 minute intervals.
After ensuring of the presence of riboflavin and observ-
ing a yellow Tyndall effect in the anterior chamber, ir-
radiation at a wavelength of 370 nanometer and power
of 3 mW/cm2 was commenced from a distance of 5 cm. Ir-
radiation was done using the UVX system (IROC, Zürich,
Switzerland). Riboflavin instillation continued every three
minutes during the 30 minutes of irradiation. At the end of
this stage, the corneal surface was rinsed with sterile bal-
anced saline solution, a soft bandage contact lens (Night &
Day, Ciba Vision, Duluth, GA) was applied, and chloram-
phenicol 0.5% eye drop was instilled. Postoperative medica-
tion included chloramphenicol 0.5% eye drops four times
daily, betamethasone 0.1%, and preservative free artificial
tears (Hypromelose) as required. Patients were examined
on day 1 and 3 after the procedure, and the lens was
removed the epithelium had healed. After removing the
lens, chloramphenicol was discontinued, and betametha-
sone was continued twice daily for another week. When
the epithelium was not healed, daily visits were continued
until complete healing. No case of intraoperative or post-
operative complication was observed.
Paraclinical tests included the assessment of uncor-
rected and best spectacle corrected visual acuity (UCVAand BCVA) using the Snellen chart, and determining the
spherical equivalent (SE) using a Retinoscope (HEINE
BETA 200, Germany). We also checked corneal topogra-
phic indices using Pentacam (Oculus Optikgerate GmbH,
Germany), corneal biomechanical parameters using the
Ocular Response Analyzer (ORA; Reichert Ophthalmic
Instruments, Buffalo, USA), and the endothelial cell count
(ECC) with a non-contact specular microscope (Konan
Medical, Hyogo, Japan).
The trend of changes was compared between the two
groups using repeated measures analysis of variance, and
intra-group differences between before and 18 months
after the procedure was assessed using the paired t test.
We chose a significance level of 0.05.
Results
Since 2 patients from each group did not show up on
the 18 month follow-up exam, 56 eyes of 56 keratoconus
patients treated with CXL (28 eyes in each group) were
compared. Their mean age was 24.32 ± 4.59 years, and
65% were male. Patients were treated with Iranian ribo-
flavin (group A) and Swiss riboflavin (group B) in two
groups of 28 people. Since the study had a non-
randomized approach, preoperative values of all parame-
ters were compared between the two groups, and there
was no significant difference in any case.
At 18 months, mean UCVA improved similarly (P =
0.684) by 0.31 ± 0.65 LogMAR (P = 0.014) in group A
and 0.24 ± 0.62 LogMAR (P = 0.082) in group B. BCVA
remained unchanged in both groups (P = 0.774). Mean
spherical refractive error reduced by 0.45 ± 1.15 D (P =
0.041) in group A and 0.27 ± 1.73 D (P = 0.458) in group
B (P = 0.655). Cylinder error and spherical equivalent
had a similar trend without any change (Table 1).
Despite similar 6 month trends between the two
groups, the 18-month decrease in max-K was 1.44 ± 1.31
D (P < 0.001) in group A and 0.52 ± 0.82 D (P = 0.007)
in group B, and the inter-group difference in was
statistically significant in this regard (P = 0.006). Mean-K
decrease was 1.33 ± 1.19 (P < 0.001) and 0.69 ± 1.00 (P =
0.004) in groups A and B, respectively; the difference
was statistically significant (P = 0.044). CCT decreased
significantly more (P = 0.004) in group A (47.00 ±
33.10 μm, P < 0.001) than group B (22.32 ± 20.87 μm,
P < 0.001). Q-value remained quite unchanged in group
A and became slightly prolate in group B; the inter-group
difference was not statistically significant (P = 0.704)
(Table 2).
The inter-group difference in corneal hysteresis
(CH) decrease was borderline significant (P = 0.062).
Corneal resistance factor (CRF) decrease was not sig-
nificantly different between the two groups (P = 0.242).
Mean ECC decreased similarly in both groups (P = 0.598)
(Table 3).
Table 1 Trend of changes in vision and refraction parameters in the two groups of keratoconus patients treated with
Iranian and Swiss preparations of riboflavin





UCVA (logMAR) Sina Darou, Iran 28 0.77 ± 0.66 0.45 ± 0.36 0.44 ± 0.41 0.014 0.684
Streuli Pharma, Switzerland 28 0.89 ± 0.56 0.79 ± 0.53 0.66 ± .47 0.082
BCVA (logMAR) Sina Darou, Iran 28 0.20 ± 0.19 0.19 ± 0.13 0.17 ± 0.13 0.710 0.774
Streuli Pharma, Switzerland 28 0.22 ± 0.20 0.20 ± 0.23 0.22 ± 0.22 0.880
Sphere (diopter) Sina Darou, Iran 28 −1.36 ± 2.18 −1.42 ± 2.36 −1.15 ± 2.25 0.041 0.655
Streuli Pharma, Switzerland 28 −1.69 ± 1.92 −1.73 ± 2.48 −1.59 ± 2.69 0.458
Cylinder (diopter) Sina Darou, Iran 28 −2.67 ± 1.83 −2.36 ± 1.79 −2.40 ± 1.77 0.827 0.642
Streuli Pharma, Switzerland 28 −2.64 ± 1.91 −2.95 ± 1.97 −2.33 ± 2.16 0.332
Spherical equivalent (diopter) Sina Darou, Iran 28 −2.69 ± 2.44 −2.60 ± 2.85 −2.35 ± 2.52 0.093 0.875
Streuli Pharma, Switzerland 28 −3.01 ± 2.29 −3.20 ± 2.80 −2.76 ± 3.12 0.230
*Intra-group comparison of parameters before and 18 months after the procedure using paired t test.
**Inter-group comparison of parameters’ trend of changes using repeated measures ANOVA.
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CXL slows down or halts the progression of keratoconus
by forming covalent bonds in the corneal stroma that
are created as an effect of free radicals. In this process,
UV-irradiated riboflavin produces free radicals, and ribo-
flavin concentration influences the level of UV absorp-
tion and strengthening reactions in the cornea. In-vivo,
riboflavin can increase UV absorption up to 95% [4].
This is while UV absorption in the cornea is only 25-35%
without riboflavin [5]. With riboflavin concentrations be-
tween 0 to 0.04%, UV absorption increases linearly, but
has no further effect [6]. Thus, using riboflavin is one of
the main pillars of the treatment.
In the 6-month report [2], we compared preliminary
clinical results of treatment with Iranian and Swiss prepa-
rations of riboflavin which demonstrated the effectiveness
of the Iranian preparation. Six-month changes in vision,
refraction, corneal topographic and biomechanical param-
eters, and ECC were similar in the two groups, and no
inter-group difference was found. Clinical parametersTable 2 Trend of changes in parameters measured with Penta
patients treated with Iranian vs. Swiss preparations of ribofla
Riboflavin No of eyes
Maximum keratometry (Diopter) Sina Darou, Iran 28
Streuli Pharma, Switzerland 28
Mean keratometry (Dipoter) Sina Darou, Iran 28
Streuli Pharma, Switzerland 28
Q-value Sina Darou, Iran 28
Streuli Pharma, Switzerland 28
Central corneal thickness (μm) Sina Darou, Iran 28
Streuli Pharma, Switzerland 28
*Intra-group comparison of parameters before and 18 months after the procedure
**Inter-group comparison of parameters’ trend of changes using repeated measurewere not significantly different at 18 months either, and
both preparations were similar in terms of stopping the
progression of keratoconus. The two preparations were
only different in terms of corneal topographic indices; bet-
ter flattening was achieved with the Iranian preparation
while CCT decrease was less with the Swiss product. It
must be noted, however, that this study was nonran-
domized, and to lessen the effect of this limitation,
we performed matching using base indices.
Stability of vision and refraction parameters in the
group treated with Sina Darou riboflavin indicated that
disease progression had stopped. Various results have
been reported after treatment with CXL. Some studies
demonstrated no change [2,7,8], some observed impro-
vement [8-10], and some showed reduced vision and
increased refraction [7]. This can be due to inter-study
differences in preoperative values or disease severity in
the study samples. Different corneal structures in differ-
ent populations can be another reason that causes such
differences. Another point is that vision assessment is acam compared between two groups of keratoconic
vin





49.05 ± 3.57 48.45 ± 2.79 47.74 ± 3.76 <0.001 0.006
48.60 ± 3.33 48.74 ± 3.56 48.06 ± 3.16 0.007
47.14 ± 3.37 46.37 ± 2.30 45.98 ± 3.78 <0.001 0.044
47.07 ± 2.91 47.00 ± 3.21 46.37 ± 3.00 0.004
−0.69 ± 0.38 −0.68 ± 0.39 −0.68 ± 0.57 0.651 0.704
−0.72 ± 0.33 −0.75 ± 0.45 −0.63 ± 0.38 0.064
482.1 ± 29.7 467.5 ± 29.8 441.5 ± 45.0 <0.001 0.004
496.9 ± 35.6 481.5 ± 37.3 474.7 ± 41.2 <0.001
using paired t test.
s ANOVA.
Table 3 Trend of changes in corneal biomechanical parameters and endothelial cell count compared between two
groups of keratoconic patients treated with Iranian vs. Swiss preparations of riboflavin





Corneal hysteresis (mmHg) Sina Darou, Iran 28 7.67 ± 1.44 6.69 ± 1.52 6.44 ± 1.37 <0.001 0.062
Streuli Pharma, Switzerland 28 7.63 ± 2.12 7.36 ± 1.50 7.53 ± 1.66 0.701
Corneal resistance factor (mmHg) Sina Darou, Iran 28 6.74 ± 1.66 6.20 ± 1.24 5.88 ± 1.93 0.023 0.242
Streuli Pharma, Switzerland 28 6.94 ± 1.97 6.94 ± 1.74 6.79 ± 1.90 0.716
Endothelial cell count (cell/mm2) Sina Darou, Iran 28 2789.3 ± 160.8 2455.4 ± 312.9 2511.7 ± 271.8 <0.001 0.176
Streuli Pharma, Switzerland 28 2731.6 ± 262.9 2470.7 ± 274.1 2574.9 ± 305.5 <0.001
*Intra-group comparison of parameters before and 18 months after the procedure using paired t test.
**Inter-group comparison of parameters’ trend of changes using repeated measures ANOVA.
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tal conditions, optometrists’ accuracy, and patients’ con-
dition. Thus, diverse results can be expected.
Corneal topographic changes were significantly different
between the two groups. Although both groups demon-
strated a significantly reduced protrusion and decreased
CCT, patients achieved better corneal flattening when
treated with Iranian riboflavin. The reduction in corneal
thickness, however, was less in the group of patients
treated with Swiss riboflavin. This could imply better
intra-fibril bond formation is supported by the Iranian
preparation due to better UVA absorption, and thus, kera-
tometry is decreased. The lack of significant inter-group
difference in ECC showed that despite better UV absorp-
tion, cytotoxic effects were not intensified, and there was
no keratocyte loss [11,12]. Some studied have demon-
strated reduced corneal thickness despite reduced kerato-
metry and halted disease progression [13-15], and this has
mostly been attributed to stages of epithelium removal
and riboflavin instillation [16].
CRF reduction was similar in the two groups. The
inter-group difference in CH reduction was borderline
significant (P = 0.062). However, CH and CRF are not
enough to show changes in corneal biomechanical proper-
ties [17], we would need to examine other indices mea-
sured with ORA to have a more accurate assessment of
the effects of these two preparations.
Conclusion
Finally, based on 18-month results, apart from better flat-
tening with the Iranian preparation and better mainten-
ance of corneal thickness with the Swiss product, cresults
in terms of clinical vision, refraction, biomechanical prop-
erties, and the endothelial cell count were comparable
with these two types preparations of riboflavin. We can
thus conclude that the Iranian riboflavin (Sina Darou) can
be an alternative for its Swiss counterpart in CXL. This
study will continue to assess the stability of results at later
follow-ups.Abbreviations
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